TY - JOUR
T1 - Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy
AU - Helbekkmo, Nina
AU - Aasebø, Ulf
AU - Sundstrøm, Stein H
AU - von Plessen, Christian
AU - Brunsvig, Paal Fr
AU - Bremnes, Roy M
AU - Norwegian Lung Cancer Study Group
PY - 2008/11
Y1 - 2008/11
N2 - BACKGROUND: There is no consensus regarding chemotherapy to patients with advanced NSCLC (ANSCLC) and performance status (PS) 2. Using data from a national multicenter study comparing two third-generation carboplatin-based regimens in ANSCLC patients, we evaluated the outcome of PS 2 patients.PATIENTS AND METHODS: The 123 PS 2 patients were compared to 309 PS 0/1 patients regarding survival, quality of life (QOL) and treatment toxicity.RESULTS: PS 2 patients had lower haemoglobin, lower global QOL and more pain, nausea/vomiting and dyspnea at inclusion. 68% of PS 2 patients received three chemotherapy courses vs. 85% in the PS 0/1 group (P<0.01). Median and 1-year survival were lower in the PS 2 group, 4.5 vs. 8.9 months and 10% vs. 37% (P<.01). More PS 2 patients needed blood transfusions (P=0.03) and hospitalization (P<0.01). In contrast, PS 2 patients had better relief of pain and dyspnea, and tended to a better global QOL and did not experience more leucopoenia, infections or bleeding.CONCLUSIONS: Despite shorter survival, treatment toxicity was acceptable and PS 2 patients achieved better improvement of pain and dyspnea and tended to better global QOL when compared to PS 0/1 patients.
AB - BACKGROUND: There is no consensus regarding chemotherapy to patients with advanced NSCLC (ANSCLC) and performance status (PS) 2. Using data from a national multicenter study comparing two third-generation carboplatin-based regimens in ANSCLC patients, we evaluated the outcome of PS 2 patients.PATIENTS AND METHODS: The 123 PS 2 patients were compared to 309 PS 0/1 patients regarding survival, quality of life (QOL) and treatment toxicity.RESULTS: PS 2 patients had lower haemoglobin, lower global QOL and more pain, nausea/vomiting and dyspnea at inclusion. 68% of PS 2 patients received three chemotherapy courses vs. 85% in the PS 0/1 group (P<0.01). Median and 1-year survival were lower in the PS 2 group, 4.5 vs. 8.9 months and 10% vs. 37% (P<.01). More PS 2 patients needed blood transfusions (P=0.03) and hospitalization (P<0.01). In contrast, PS 2 patients had better relief of pain and dyspnea, and tended to a better global QOL and did not experience more leucopoenia, infections or bleeding.CONCLUSIONS: Despite shorter survival, treatment toxicity was acceptable and PS 2 patients achieved better improvement of pain and dyspnea and tended to better global QOL when compared to PS 0/1 patients.
KW - Antineoplastic Combined Chemotherapy Protocols
KW - Carboplatin
KW - Carcinoma, Non-Small-Cell Lung
KW - Deoxycytidine
KW - Humans
KW - Kaplan-Meier Estimate
KW - Karnofsky Performance Status
KW - Lung Neoplasms
KW - Quality of Life
KW - Treatment Outcome
KW - Vinblastine
U2 - 10.1016/j.lungcan.2008.03.003
DO - 10.1016/j.lungcan.2008.03.003
M3 - Journal article
C2 - 18417246
VL - 62
SP - 253
EP - 260
JO - Lung Cancer
JF - Lung Cancer
SN - 0169-5002
IS - 2
ER -